Navigation Links
deCODE genetics Announces Second Quarter 2008 Financial Results
Date:8/6/2008

enue was $30.0 million, compared to $16.2 million for the same period last year. As of June 30, 2008, the company had $15.1 million in deferred revenue that will be recognized over future reporting periods. The period-on-period increase in revenue for the second quarter and first half of 2008 was driven principally by growth in the company's genomic services business, which includes the company's diagnostics, deCODEme(TM) personal genome analysis, and contract genotyping businesses.

Research and development expense was $8.0 million for the second quarter of this year, compared to $14.5 million for the same period last year. For the first six months of 2008, R&D expense was $20.6 million, compared to $27.2 million for the first six months of 2007. Our research and development expense in the first six months of the year reflects the conclusion of clinical pharmacology studies in our most advanced drug development programs, the launch of our prostate cancer and glaucoma diagnostics tests, and the advancement of gene and target discovery work in a range of major disease areas.

Selling, general and administrative expense for the second quarter of 2008 was $7.1 million, compared to $6.8 million for the 2007 period. For the first half of the year, SG&A expense was $14.4 million in 2008 and $12.3 million in 2007. The increases in SG&A expense year-on-year reflect principally the build-up of our sales efforts for the company's diagnostics and deCODEme(TM) businesses.

At June 30, 2008, the company had $49.4 million in cash and investments. This includes $23.7 million in cash, cash equivalents and current investments, $5.1 million in restricted cash equivalents, and $20.6 million in non-current investments in auction rate securities. At December 31, 2007, the company had $94.1 million in cash, cash equivalents, restricted cash equivalents, and investments.

"Our results for the second quarter reflect our focus on capturing the commercial opportunitie
'/>"/>

SOURCE deCODE genetics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. deCODE genetics to Webcast Presentation at Thomas Weisel Partners Annual Healthcare Conference
2. deCODE genetics Announces Webcast of Conference Call to Discuss Third Quarter 2007 Financial Results
3. deCODE genetics Announces Third Quarter 2007 Financial Results
4. deCODE Launches deCODEme(TM)
5. deCODE genetics to Webcast Presentation at JPMorgan Annual Healthcare Conference
6. deCODE Discovers Gene Variants that May Help to Distribute the Work of Evolution between Men and Women
7. deCODE genetics to Webcast Presentation at BIO CEO and Investor Conference
8. deCODE genetics Announces Webcast of Conference Call to Discuss Full-year 2007 Financial Results
9. deCODE Genetics Announces Full-year 2007 Financial Results
10. deCODE genetics to Webcast Presentation at Lehman Brothers Eleventh Annual Global Healthcare Conference
11. deCODE genetics to Webcast Presentation at 15th Annual Future Leaders in the Biotech Industry Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... (PRWEB) January 23, 2015 Biofertilizers stimulate ... such as nitrogen and phosphorous through the activities in ... biofertilizers is increasing due to the stress on reducing ... fertilizers. , The report defines and segments the bio ...
(Date:1/22/2015)... RBJ today announces the firm brokered a long-term lease totaling ... biopharmaceutical company, at Two Ledgemont Center in Lexington, ... president, and Brian Cohen , senior vice president, represented ... 95 Hayden Ave. Photo - http://photos.prnewswire.com/prnh/20150122/170765 ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Protocol Networks ... The growing team of brand-neutral, independent consultants, Protocol Networks ... Rogers explained that over the years, his company has ... Moroso, Town of Plainfield, as well as others. With ...
(Date:1/22/2015)... Wilmington, DE (PRWEB) January 22, 2015 ... the Pistoia Alliance, which helps companies check the legal ... set to expand to China. , As their ... companies are globally adopting software solutions built as a ...
Breaking Biology Technology:Biofertilizers Market Expected to Reach $1,649.7 Million by 2019 - New Report By MarketsandMarkets 2Biofertilizers Market Expected to Reach $1,649.7 Million by 2019 - New Report By MarketsandMarkets 3Biofertilizers Market Expected to Reach $1,649.7 Million by 2019 - New Report By MarketsandMarkets 4Transwestern | RBJ Advises Shire in 202,000 SF Lease, Creating Boston's Largest Suburban Biotech Campus 2Protocol Networks Brings Independent Technology Consulting to the Constitution State 2Global Compliance Service for Controlled Substances to Expand to China 2
... AEterna Zentaris Inc. (NASDAQ: AEZS ; TSX: ... on endocrine therapy and oncology, today announced that ... clinical development of the growth hormone secretagogue (GHS) ... be the first oral diagnostic test approved for ...
... BEIJING, Oct. 19 /PRNewswire-Asia-FirstCall/ -- China Medical Technologies,Inc. ... medical device,company that develops, manufactures and markets advanced in-vitro ... for its SPR-,based analysis system (the "SPR System") from ... , The SPR System utilizes ...
... , PHILADELPHIA, Oct. 17 UCB today announced data ... function, pain and fatigue of rheumatoid arthritis (RA) as ... of structural joint damage (seen at week 24) following ... was sustained up to 100 weeks. Cimzia® is approved ...
Cached Biology Technology:AEterna Zentaris to Complete Phase 3 Clinical Trial of Macimorelin (AEZS-130) as First Oral Diagnostic Test for Growth Hormone Deficiency 2AEterna Zentaris to Complete Phase 3 Clinical Trial of Macimorelin (AEZS-130) as First Oral Diagnostic Test for Growth Hormone Deficiency 3China Medical Technologies Announces the SFDA Approval for its SPR System 2China Medical Technologies Announces the SFDA Approval for its SPR System 3UCB's Cimzia(R) (certolizumab pegol), Shows Rapid and Sustained Clinical Response in Adult Patients Living with Moderate to Severe Rheumatoid Arthritis 2UCB's Cimzia(R) (certolizumab pegol), Shows Rapid and Sustained Clinical Response in Adult Patients Living with Moderate to Severe Rheumatoid Arthritis 3UCB's Cimzia(R) (certolizumab pegol), Shows Rapid and Sustained Clinical Response in Adult Patients Living with Moderate to Severe Rheumatoid Arthritis 4UCB's Cimzia(R) (certolizumab pegol), Shows Rapid and Sustained Clinical Response in Adult Patients Living with Moderate to Severe Rheumatoid Arthritis 5UCB's Cimzia(R) (certolizumab pegol), Shows Rapid and Sustained Clinical Response in Adult Patients Living with Moderate to Severe Rheumatoid Arthritis 6UCB's Cimzia(R) (certolizumab pegol), Shows Rapid and Sustained Clinical Response in Adult Patients Living with Moderate to Severe Rheumatoid Arthritis 7UCB's Cimzia(R) (certolizumab pegol), Shows Rapid and Sustained Clinical Response in Adult Patients Living with Moderate to Severe Rheumatoid Arthritis 8UCB's Cimzia(R) (certolizumab pegol), Shows Rapid and Sustained Clinical Response in Adult Patients Living with Moderate to Severe Rheumatoid Arthritis 9UCB's Cimzia(R) (certolizumab pegol), Shows Rapid and Sustained Clinical Response in Adult Patients Living with Moderate to Severe Rheumatoid Arthritis 10UCB's Cimzia(R) (certolizumab pegol), Shows Rapid and Sustained Clinical Response in Adult Patients Living with Moderate to Severe Rheumatoid Arthritis 11UCB's Cimzia(R) (certolizumab pegol), Shows Rapid and Sustained Clinical Response in Adult Patients Living with Moderate to Severe Rheumatoid Arthritis 12
(Date:1/22/2015)... NXTD and NXTDW) a biometric authentication company focused on ... Wocket™ smart wallet at CES 2015 in Las Vegas ... the "11 Hot Products at CES" in a review published in Wired.com, ... Newseveryday.com and "The top 10 gadgets from CES 2015" by Danny ...
(Date:1/22/2015)... NEW YORK , Jan. 22, 2015   EyeLock, Inc. ... announced it has appointed Steve Gerber to the ... Gerber will be responsible for leading development of mobile platforms ... 25 years of success and innovation in the semiconductor industry ...
(Date:12/22/2014)... , Dec. 22, 2014  The 2014 Holiday Season may ... Acuity Market Intelligence reports that the long anticipated floodgates ... that intensifying demand for smart phones, tablets, and wearable ... market of 2.5 billion users with nearly 4.8 billion ...
Breaking Biology News(10 mins):CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 3EyeLock Names Steve Gerber as Senior Vice President of Mobile and Wearables 2First Season of Holiday Shopping with Mobile Biometric Payments Wraps Up With a Present for Biometrics Industry: A Rosy Forecast for More Than 2 Billion Users of 4.8 Billion Mobile Biometric Devices by 2020 2
... A team composed of Harvard students and alumni was ... 2008 Development Marketplace competition, held in Accra, Ghana from ... cell-based lighting systems suitable for Sub-Saharan Africa, netted the ... Bank, as only 26 percent of Africas population has ...
... Its a paradox that has confounded evolutionary biologists since ... Since parasites depend on their hosts for survival, why do ... Emory University study of monarch butterflies and the microscopic parasites ... strike a middle ground between the benefits gained by reproducing ...
... a stalwart stand-in for humans in medical research, thanks ... genes may behave differently in mouse and man, a ... and Jianzhi Zhang reveals. Their results, which have ... human disease, appear in the current issue of the ...
Cached Biology News:Undergraduates develop 'dirt-powered' microbial fuel cells to light Africa 2Undergraduates develop 'dirt-powered' microbial fuel cells to light Africa 3Monarch butterflies help explain why parasites harm hosts 2Monarch butterflies help explain why parasites harm hosts 3Mouse can do without man's most treasured genes 2Mouse can do without man's most treasured genes 3
... ErbB 2 - BSA and Azide ... tested applications). Antigen: ... KLH, corresponding to C terminal amino ... Entrez GeneID: 2064 ...
SHP-2 Antibody...
Sheep polyclonal to ErbB 2 ( Abpromise for all tested applications). Antigen: Recombinant full length c-ErbB2 protein (Human). Entrez GeneID: 2064 Swiss Protein ID: P04626...
Mouse monoclonal [RIZ1723] to PRDM2/RIZ...
Biology Products: